Evidence map›Paper›PMID 39209814›Full record

ArticleNature communications2024

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue.

Richard D Bell, Matthew Brendel, Maxwell A Konnaris, Justin Xiang, Miguel Otero, Mark A Fontana, Zilong Bai, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Daria M Krenitsky, Nida Meednu and 14 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Richard D Bell *Arthritis and Tissue Degeneration Program and Research Institute, Hospital for Special Surgery, New York, NY, USA. bellr@hss.edu.ORCID 0000-0003-1562-3879
Matthew Brendel *Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-3417-4597
Maxwell A KonnarisHuck Institute of the Life Sciences, Pennsylvania State University, State College, University Park, PA, USA.
Justin XiangHorace Greely High School, Chappaqua, NY, USA.
Miguel OteroWeill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-4945-2994
Mark A FontanaArthritis and Tissue Degeneration Program and Research Institute, Hospital for Special Surgery, New York, NY, USA.ORCID 0000-0002-0529-9035
Zilong BaiDepartment of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-3891-8015
Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium
Daria M KrenitskyAllergy, Immunology and Rheumatology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Nida MeednuAllergy, Immunology and Rheumatology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-2868-3339
Javier Rangel-MorenoAllergy, Immunology and Rheumatology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-9738-1182
Dagmar Scheel-ToellnerRheumatology Research Group, Institute for Inflammation and Ageing, University of Birmingham, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.
Hayley CarrRheumatology Research Group, Institute for Inflammation and Ageing, University of Birmingham, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.
Saba NayarRheumatology Research Group, Institute for Inflammation and Ageing, University of Birmingham, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.ORCID 0000-0002-4350-110X
Jack McMurrayRheumatology Research Group, Institute for Inflammation and Ageing, University of Birmingham, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.
Edward DiCarloDepartment of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY, USA.
Jennifer H AnolikAllergy, Immunology and Rheumatology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-1450-1549
Laura T DonlinArthritis and Tissue Degeneration Program and Research Institute, Hospital for Special Surgery, New York, NY, USA.ORCID 0000-0002-1428-090X
Dana E OrangeArthritis and Tissue Degeneration Program and Research Institute, Hospital for Special Surgery, New York, NY, USA.
H Mark KenneyCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-0598-3232
Edward M SchwarzCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-4854-9698
Andrew FilerRheumatology Research Group, Institute for Inflammation and Ageing, University of Birmingham, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.ORCID 0000-0001-8164-6249
Lionel B IvashkivArthritis and Tissue Degeneration Program and Research Institute, Hospital for Special Surgery, New York, NY, USA.ORCID 0000-0002-9951-0646
Fei WangDepartment of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0001-9459-9461

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
University of Rochester Mentoring Environment: Nurturing Training Opportunities in Research (UR-MENTOR)T32GM007356 · NIGMS · UNIVERSITY OF ROCHESTER · PI O'BANION, M. KERRY · 1985 to 2023
$15.1M
CYTOKINE REGULATION OF RA SYNOVIOCYTE PHENOTYPER01AR046713 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 1999 to 2025
$8.3M
Fc Receptors &Cytokine Balance in Rheumatoid ArthritisR01AR050401 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Lionel B Ivashkiv · 2004 to 2026
$7.4M
Pain and synovial pathotypes in AMP AIMUC2AR081025 · NIAMS · UNIVERSITY OF ROCHESTER · PI Jennifer Howitt Anolik, Laura T. Donlin · 2022 to 2026
$7.2M
Elucidating the Mechanisms of Arthritic Flare and Developing TreatmentsR01AR056702 · NIAMS · UNIVERSITY OF ROCHESTER · PI SCHWARZ, EDWARD M. · 2009 to 2025
$4.9M
Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid ArthritisR01AR078268 · NIAMS · STANFORD UNIVERSITY · PI ORANGE, DANA ELIZABETH, ROBINSON, WILLIAM H · 2021 to 2025
$3.1M
Cellular Dynamics at the Synovium-Bone interface in RAUH2AR067690 · NIAMS · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2014 to 2020
$3.0M
Role of T-bet B cells in rheumatoid arthritisR01AI175212 · NIAID · UNIVERSITY OF ROCHESTER · PI Jennifer Howitt Anolik, Javier Rangel-Moreno · 2024 to 2026
$2.1M
Laser Capture as a Novel Tool to Dissect B Cell Roles in Rheumatoid ArthritisR21AR071670 · NIAMS · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2017 to 2018
$367k
Elucidating the Mechanisms of Lymphatic Muscle Cell Dysfunction in Aging and InflammationF30AG076326 · NIA · UNIVERSITY OF ROCHESTER · PI KENNEY, HOWARD MARK · 2022 to 2023
$98k
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI175212NIAMS NIH HHS R01 AR046713NIAMS NIH HHS R01 AR050401NIAMS NIH HHS R01 AR056702NIAMS NIH HHS R01 AR078268NIAMS NIH HHS R21 AR071670NIAMS NIH HHS UC2 AR081025NIAMS NIH HHS UH2 AR067690NIA NIH HHS F30 AG076326NIGMS NIH HHS T32 GM007356U.S. Department of Health Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) AR050401
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a complex immune-mediated inflammatory disorder in which patients suffer from inflammatory-erosive arthritis. Recent advances on histopathology heterogeneity of RA synovial tissue revealed three distinct phenotypes based on cellular composition (pauci-immune, diffuse and lymphoid), suggesting that distinct etiologies warrant specific targeted therapy which motivates a need for cost effective phenotyping tools in preclinical and clinical settings. To this end, we developed an automated multi-scale computational pathotyping (AMSCP) pipeline for both human and mouse synovial tissue with two distinct components that can be leveraged together or independently: (1) segmentation of different tissue types to characterize tissue-level changes, and (2) cell type classification within each tissue compartment that assesses change across disease states. Here, we demonstrate the efficacy, efficiency, and robustness of the AMSCP pipeline as well as the ability to discover novel phenotypes. Taken together, we find AMSCP to be a valuable cost-effective method for both pre-clinical and clinical research.

Indexed as

Arthritis, RheumatoidSynovial MembraneAnimalsComputational BiologyHumansInflammationMicePhenotype

Identifiers

PMID39209814
PMCPMC11362542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.